Evotec AG announced today that it will make a strategic investment as part of Facio Therapies‘ („Facio“) 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy („FSHD“) community (Total volume: EUR 4.8 m). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-strategic-investment-in-facio-therapies-to-support-development-of-novel-fshd-therapy-5470